---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-011398"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2022-02-03T23:59:59+00:00"
generated_at: "2026-06-27T11:44:45.307868+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics appoints ex-Biogen EVP Alfred Sandrock to board, names Robin Swartz COO

## Summary
- Alfred Sandrock, former Biogen EVP R&D, appointed to Board effective Feb 7, 2022; consulting agreement at $30k/month.
- Robin Swartz promoted to COO; base salary $420k, target bonus 40%, and option grant of 65,000 shares.
- Sandrock receives standard director compensation: $40k annual cash, initial option for 44,000 shares, plus committee fees.
- Swartz's employment extends COBRA premium payments to 12 months on qualifying termination.
- Both appointments effective Feb 7, 2022; Sandrock's term runs until 2023 annual meeting.

## SEC filing metadata
- accession: 0001104659-22-011398
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2022-02-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/0001104659-22-011398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/tm225066d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-011398
- JSON: https://secwatch.observer/filing/0001104659-22-011398.json
- Plain text: https://secwatch.observer/filing/0001104659-22-011398.txt

## Key facts
- Executive change
  Alfred Sandrock, M.D., Ph.D. was appointed as director at Voyager Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: appointed Alfred Sandrock, M.D., Ph.D. as a director of the Company and as a member of both the Executive Committee and the Science and Technology Committee of the Board, effective February 7, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/0001104659-22-011398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.